Reinventing bone marrow transplantation: Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect

ONCOLOGY

Volumn 13, Issue 5, 1999, Pages 621-628

  Champlin, Richard ^a   Khouri, Issa ^a   Komblau, Stephen ^a   Molidrem, Jeffrey ^a   Giralt, Sergio ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA; LEUKEMIA CELL; RELAPSE; REVIEW; T LYMPHOCYTE SUBPOPULATION;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST REACTION; HUMANS; NEOPLASMS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY;

EID: 0033021543     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Thomas ED: Bone marrow transplantation for malignant disease. J Clin Oncol 1:517, 1983.
2. Thomas ED: The role of bone marrow transplantation for eradication of malignant disease. Cancer 10:1963-1969, 1969.
3. Weiden PL, Sullivan KM, Flournoy N, et al: The Seattle Marrow Transplant Team: Antileukemic effect of chronic graft-vs-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529-1532, 1981.
4. Horowitz MM, Gale RP, Sondel PM, et al: Graft-vs-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990.
5. Sullivan KM, Storb R, Buckner CD, et al: Graft-vs-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320:828-834, 1989.
6. Gale RP, Champlin RE: How does bone marrow transplantation cure leukemia? Lancet 2:28-30, 1984.
7. Fefer A, Cheever MA, Greeberg PD: Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 76:1269-1271, 1986.
8. Gale RP, Horowitz MM, Ash RC, et al: Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646-652, 1994.
9. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995.
10. Antin JH: Graft-vs-leukemia: No longer an epiphenomenon. Blood 82:2273-2277, 1993.
11. Drobyski WR, Keever CA, Roth MS, et al: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310-2318, 1993.
12. Radich JP, Gehly G, Gooley T, et al: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients. Blood 85:2632-2638, 1995.
13. Hughes TP, Morgan GJ, Martial P, et al: Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse. Blood 77:874-878, 1991.
14. Collins RH, Jr, Shpilberg O, Drobyski WR, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997.
15. Cullis JO, Jiang YZ, Schwarer AP, et al: Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 79:1379-1381, 1992.
16. Van Rhee F, Savage D, Blackwell J, et al: Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 21:1055-1061, 1998.
17. Van Rhee F, Lin F, Cullis JO, et al: Relapse of chronic myeloid leukemia after a llogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-3383, 1994.
18. Marmont AM, Horowitz MM, Gale RP, et al: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130, 1991.
19. Papadopoulos EB, Carabasi MH. Castro-Malaspina H, et al: T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-vs-host disease. Blood 91:1083-1090, 1998.
20. Cardoso AA, Seamon MJ, Afonso HM, et al: Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90:549-561, 1997.
21. Brenner M, Porcelli S: Antigen presentation: A balanced diet. Science 277:332, 1997.
22. Van Besien KW, Khouri IF, Giralt SA, et al: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 13:1096-1102, 1995.
23. Van Besien K, Sobocinski K, Rowlings PA, et al: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92:1832-1836, 1998.
24. Khouri IF, Przepiorka D, Van Besien K, et al: Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: Timing of transplantation and potential effect of fludarabine on acute graft-vs-host disease. Br J Haematol 97:466-473, 1997.
25. Michallet M, Archimbaud E, Bandini G, et al: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124:311-315, 1996.
26. Rondón G, Giralt S, Huh Y, et al: Graft-vs-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18:669-672, 1996.
27. Van Besien KW, De Lima M, Giralt SA, et al: Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-vs-lymphoma effect. Bone Marrow Transplant 19:977-982, 1997.
28. Khouri I, Keating MJ, Przepiorka D, et al: Engraftment and induction of GVL with fludarabine-based non-ablative preparative regimen in patients with chronic lymphocytic leukemia. Blood 88(suppl 1):301a, 1996.
29. Lokhorst HM, Schattenberg A, Comelissen JJ, et al: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90:4206-4211, 1997.
30. Tricot G, Vesole DH, Jagannath S, et al: Graft-vs-myeloma effect: Proof of principle. Blood 87:1196-1198, 1996.
31. Verdonck LF, Lokhorst HM, Dekker AW, et al: Graft-vs-myeloma effect in two cases. Lancet 347:800-801, 1996.
32. Goulmy E, Voogt P, Van Els C, et al: The role of minor histocompatibility antigens in GVHD and rejection: A mini-review. Bone Marrow Transplant 1(suppl):49-51, 1991.
33. Falkenburg JHF, Goselink HM, Van der Harst D, et al: Growth inhibition of clonogeneic leukemic precursor cells by minor histocompatibility antigen specific cytotoxic T lymphocytes. J Exp Med 174:27-33, 1991.
34. Faber LM, Van der Hoeven J, Goulmy E, et al: Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 96:877-883, 1995.
35. Jiang Y-Z, Kanfer EJ, Macdonald D, et al: Graft-vs-leukaemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant 8:253-258, 1991.
36. Sosman JA, Oettel KR, Smith SD, et al: Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are cross reactive with determinants present on unrelated nonleukemic cells. Blood 75:2005-2016, 1990.
37. Molldrem JJ, Clave E, Jiang YZ, et al: Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90:2529-2534, 1997.
38. Molldrem J, Dermime S, Parker K, et al: Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88:2450-2457, 1996.
39. Ueno NT, Rondón G, Mirza NQ, et al: Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986-993, 1998.
40. Eibl B, Schwaighofer H, Nachbaur D, et al: Evidence for a graft-vs-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-1508, 1996.
41. Korngold R, Sprent J: T cell subsets and graft-vs-host disease. Transplantation 44:335-339, 1987.
42. Korngold R, Sprent J: Variable capacity of L3 T4 + T cells to cause lethal graft-vs-host disease across minor histocompatibility barriers in mice. J Exp Med 165:52-64, 1987.
43. Ferrara JLM, Deeg HJ: Mechanisms of disease: Graft-vs-host disease. N Engl J Med 324:667-674, 1991.
44. Ferrara JLM, Abhyankar S, Gilliland DG: Cytokine storm of graft-vs-host disease: A critical effector role for interleukin-1. Transplant Proc 25:1216-1217, 1993.
45. Faber LM, Van Luxemburg-Heijs SAP, Willemze R, et al: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283-1289, 1992.
46. Van der Harst D, Goulmy E, Falkenburg JHF, et al: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83:1060-1066, 1994.
47. Truitt RL, Atasoylu AA: Contribution of CD4+ and CD8+ T cells to graft-vs-host disease and graft-vs-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 8:51-58, 1991.
48. Okunewick IP, Kociban DL, Machen LL, et al: Evidence for a possible role of Asialo-GM 1-positive cells in the graft-vs-leukemia repression of a murine type-C retroviral leukemia. Bone Marrow Transplant 16:451-456, 1995.
49. Jiang Y-Z, Barrett AJ: Cellular and cytokine mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp Hematol 23:1167-1172, 1995.
50. Jiang YZ, Mavroudis D, Dermime S, et al: Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 93:606-612, 1996.
51. Jiang YZ, Barrett AJ, Goldman JM, et al: Association of natural killer cell immune recovery with a graft-vs-leukemia effect independent of graft-vs-host disease following allogeneic bone marrow transplantation. Ann Hematol 74:1-6, 1997.
52. Zeis M, Uharek L, Glass B, et al: Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 59:1734-1736, 1995.
53. Glass B, Uharek L, Zeis M, et al: Graft-vs-leukaemia activity can be predicted by natural cytotoxicity against leukaemia. Br J Haematol 93:412-420, 1996.
54. Hauch M, Gazzola MV, Small T, et al: Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250-2262, 1990.
55. Giralt SA, Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation: A review. Blood 84:3603-3612, 1994.
56. Hoffmann T, Theobald M, Bunjes D, et al: Frequency of bone marrow T-cells responding to HLA-identical non-leukemic and leukemic stimulator cells. Bone Marrow Transplant 12:1-8, 1993.
57. Keil F, Haas OA, Fritsch G, et al: Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood 89:3113-3117, 1997.
58. MacKinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-vs-leukemia responses from graft-vs-host disease. Blood 86:1261-1268, 1995.
59. Bacigalupo A, Soracco M, Vassallo F, et al: Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 19:927-932, 1997.
60. Rabman SL, Mahendra P, Nacheva E, et al: Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML. Bone Marrow Transplant 21:955-956, 1998.
61. Giralt S, Hester J, Huh Y, et al: CD8+ depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Graft vs leukemia without graft vs host disease. Blood 86:4337-4343, 1995.
62. Alyea EP, Soiffer RI, Canning C, et al: Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 91:3671-3680, 1998.
63. Bonini C, Ferrari G, Verzeletti S, et al: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-vs-leukemia. Science 276:1719-1724, 1997.
64. Munshi NC, Govindarajan R, Drake R, et al: Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 89:1334-1340, 1997.
65. Tiberghien P, Reynolds CW, Keller J, et al: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation. Blood 84:1333-1341, 1994.
66. Cavazzana-Calvo M, Stephan JL, Samacki S, et al: Attenuation of graft-vs-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 83:288-298, 1994.
67. Mavroudis DA, Dermime S, Molldrem J, et al: Specific depletion of alloreactive T cells in HLA-identical siblings: A method for separating graft-vs-host and graft-vs-leukaemia reactions. Br J Haematol 101:565-570, 1998.
68. Ship AM, Carter R, Murray T, et al: Irradiated donor lymphocyte infusion, a novel approach to prevent graft failure during allogeneic bone marrow transplant (abstract). Proc Am Soc Clin Oncol 17:74a, 1998.
69. Rooney CM, Smith CA, Ng CYC, et al: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13, 1995.
70. Walter EA, Greenberg PD, Gilbert MJ, et al: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038-1044, 1995.
71. Smit WM, Rijnbeek M, Van Bergen CAM, et al: Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplant 21:553-560, 1998.
72. Champlin RE: Separation of graft-vs-host disease and graft-vs-leukemia against chronic myelogenous leukemia. Exp Hematol 23:1148-1151, 1995.
73. Giralt S, Gajewski J, Khouri I, et al: Induction of graft-vs-leukemia as primary treatment of chronic myelogenous leukemia. Blood 90(suppl 1):1857a, 1997.
74. Khouri I, Keating M, Korbling M, et al: Transplant lite: Induction of graft-vs-leukemia using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998.
75. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998.
76. Storb R, Yu C, Wagner JL, et al: Stable mixed hematopoietic chimerism in DLA-identical litter mate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048-3054, 1997.
77. Antin Jill, Ferrara JLM: Cytokine dysregulation and acute graft-vs-host disease. Blood 80:2964-2968, 1992.
78. Hill GR, Crawford JM, Cooke KR, et al: Total body irradiation and acute graft-vs-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204-3213, 1997.
79. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-vs-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997.
80. Bensinger WI, Buckner CD, Anasetti C, et al: Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 88:2787-2793, 1996.
81. Gahrton G, Tura S, Ljungman P, et al: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312-1322, 1995.
82. Giralt S, Cohen A, Mehra R, et al: Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 90:1853a, 1997.
83. McSweeny PA, Wagner JL, Maloney DG, et al: Outpatient PBSC allografts using immunosuppression with low dose TBI before, and cyclosporine and mycophenolate mofetil after transplant. Blood 92(suppl 1):519a , 1998.
84. Kelemen E, Masszi T, Reményi P, et al: Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination. Bone Marrow Transplant 21:747-749, 1998.
85. Bacigalupo A, Van Lint MT, Occhini D, et al: Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77:1423-1428, 1991.